Academic Journal
Aptamer conjugated and oleuropein loaded PLGA nanoparticles increase the apoptosis of breast cancer cells.
| Τίτλος: | Aptamer conjugated and oleuropein loaded PLGA nanoparticles increase the apoptosis of breast cancer cells. |
|---|---|
| Συγγραφείς: | Sharma P; Division of Cell Biology and Immunology, Biomedical Parasitology and Translational-immunology Lab, CSIR-Institute of Microbial Technology (IMTECH), Sec-39A, Chandigarh, 160036, India. Electronic address: prakriti.sh10@gmail.com., Devi S; Division of Cell Biology and Immunology, Biomedical Parasitology and Translational-immunology Lab, CSIR-Institute of Microbial Technology (IMTECH), Sec-39A, Chandigarh, 160036, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India., Negi S; Division of Cell Biology and Immunology, Biomedical Parasitology and Translational-immunology Lab, CSIR-Institute of Microbial Technology (IMTECH), Sec-39A, Chandigarh, 160036, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India., Khajuria A; University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, 160014, India., Kaur J; University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, 160014, India., Rana K; International Centre for Genetic Engineering and Biotechnology, New Delhi, India., Alajangi HK; Department of Biophysics, Panjab University, Chandigarh, 160014, India., Kumar R; Department of Biotechnology, Galgotias Multi-Disciplinary Research & Development Cell (G-MRDC)), Galgotias University, Greater Noida, UP, 201308, India., Sharma U; Department of Human Genetics and Molecular Medicine, Central University of Punjab, Bathinda, Punjab, India., Rai G; Department of Molecular and Human Genetics, Institute of Science, Banaras Hindu University, Varanasi, 221005, India., Rao A; CSIR-Institute of Microbial Technology (IMTECH), Sec-39A, Chandigarh, 160036, India., Barnwal RP; Department of Biophysics, Panjab University, Chandigarh, 160014, India., Singh G; University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, 160014, India., Tandel N; Department of Biotechnology, VNSGU, Surat, Gujarat, 395007, India. Electronic address: nikunj.tandel@nirmauni.ac.in., Tyagi RK; Division of Cell Biology and Immunology, Biomedical Parasitology and Translational-immunology Lab, CSIR-Institute of Microbial Technology (IMTECH), Sec-39A, Chandigarh, 160036, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India. Electronic address: rajeev.gru@gmail.com. |
| Πηγή: | Biochemical and biophysical research communications [Biochem Biophys Res Commun] 2026 Oct 22; Vol. 836, pp. 154583. Date of Electronic Publication: 2026 Sep 12. |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Elsevier Country of Publication: United States NLM ID: 0372516 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1090-2104 (Electronic) Linking ISSN: 0006291X NLM ISO Abbreviation: Biochem Biophys Res Commun Subsets: MEDLINE |
| Imprint Name(s): | Publication: <2002- >: San Diego, CA : Elsevier Original Publication: New York, Academic Press. |
| Ιατρικοί όροι (MeSH): | Apoptosis*/drug effects , Breast Neoplasms*/pathology , Breast Neoplasms*/drug therapy , Breast Neoplasms*/metabolism , Nanoparticles*/chemistry , Iridoids*/administration & dosage , Iridoids*/pharmacology , Iridoids*/chemistry , Aptamers, Nucleotide*/chemistry , Polyglycolic Acid*/chemistry , Lactic Acid*/chemistry, Polylactic Acid-Polyglycolic Acid Copolymer/chemistry ; Forkhead Box Protein O1/metabolism ; Forkhead Box Protein O1/genetics ; Mucin-1/metabolism ; Cell Survival/drug effects ; Proto-Oncogene Proteins c-akt/metabolism ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/chemistry ; Proto-Oncogene Proteins c-bcl-2/metabolism ; Proto-Oncogene Proteins c-bcl-2/genetics ; Humans ; MDA-MB-231 Cells ; Iridoid Glucosides ; Female ; Cell Line, Tumor |
| Περίληψη: | Newer therapeutic strategies aim to increase the sensitivity of cancer cells to apoptosis. The phytochemical, oleuropein (OLP) has shown promising anticancer properties; however, its low bioavailability and non-specific delivery limit its anticancer potential. Therefore, we developed a novel aptamer-conjugated nanocarrier delivery system for the targeted, efficient and controlled delivery of OLP to the MDA-MB-231 breast cancer cells. The oleuropein-loaded nanoparticles (OLP-NPs) were synthesized, characterized, and conjugated with a Mucin-1 specific aptamer (APT) (APT-OLP-NPs) for an efficient delivery of OLP. Characterized APT-OLP-NPs formulation exhibited a small hydrodynamic diameter and negative zeta potential driving the efficient cellular uptake. The increases nanoparticle size following the aptamer conjugation as compared to the OLP-NPs, confirmed the successful surface functionalization. The latter supported the targeting ability of the developed formulation. APT-OLP-NPs significantly reduced MDA-MB-231 cell viability and induced apoptosis as confirmed by the changes seen in the relative mRNA expression of apoptosis-related genes, including Bcl-2 family members. Protein-level analysis validating the transcripts expression of immune markers suggested that this anticancer effect of OLP is driven by Akt1 signaling. This pathway controls the expression of NF-κB and guides the transcription factor FOXO1 to regulate apoptosis. Overall, our findings demonstrate increased apoptosis in aggressive breast cancer cells. (Copyright © 2026 Elsevier Inc. All rights reserved.) |
| Competing Interests: | Declaration of competing interest Authors declare no conflict of interest exists. |
| Contributed Indexing: | Keywords: Apoptosis; Cancer cells; Inflammation; Macrophages; Oxidative stress; Signaling |
| Substance Nomenclature: | 2O4553545L (oleuropein) 0 (Iridoid Glucosides) 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer) 0 (Iridoids) 0 (Forkhead Box Protein O1) 0 (Aptamers, Nucleotide) 0 (FOXO1 protein, human) 0 (Mucin-1) EC 2.7.11.1 (Proto-Oncogene Proteins c-akt) 26009-03-0 (Polyglycolic Acid) 33X04XA5AT (Lactic Acid) 0 (Antineoplastic Agents) 0 (MUC1 protein, human) 0 (Proto-Oncogene Proteins c-bcl-2) |
| Entry Date(s): | Date Created: 20260915 Date Completed: 20260930 Latest Revision: 20260930 |
| Update Code: | 20261001 |
| DOI: | 10.1016/j.bbrc.2026.154583 |
| PMID: | 42743749 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1090-2104 |
|---|---|
| DOI: | 10.1016/j.bbrc.2026.154583 |